A Phase 3 interventional study of Brivaracetam in Epilepsy, sponsored by UCB Pharma. Completed at 58 sites in 11 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-07-11.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 14th largest by enrollment, is one of 4 that started in 2008, is one of 21 in phase 3, and was the 14th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2008.
This study's enrollment of 108 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 55th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2008, is one of 74 in phase 3, and was the 56th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16 years and older with epilepsy. This study permits continued access to treatment for subjects who participated in a previous epilepsy study. The study will explore the long-term safety and efficacy of brivaracetam.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Brivaracetam at flexible dosing up to 200mg /day
Drug: Brivaracetam
Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
Also known as: ucb 34714
Percentage of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)
Treatment-emergent Adverse events (TEAE) are any untoward medical occurrences in a subject during administered study treatment, whether or not these events are related to study treatment.
Time frame: During the Evaluation Period (up to 9 years)
Percentage of Subjects Who Withdrew Due to Adverse Event (AE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)
Adverse Events (AE) are any untoward medical occurrences in a subject during administered study treatment, whether or not these events are related to study treatment.
Time frame: During the Evaluation Period (up to 9 years)
Percentage of Subjects With a Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)
An SAE was any untoward medical occurrence that, at any dose resulted in death, was life threatening, required in-subject hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.
Time frame: During the Evaluation Period (up to 9 years)
Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 3 Months of the Evaluation Period (up to 9 Years)
BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.
Time frame: During the Evaluation Period (up to 9 years)
Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 6 Months, of the Evaluation Period (up to 9 Years)
BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.
Time frame: During the Evaluation Period (up to 9 years)
Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 12 Months of the Evaluation Period (up to 9 Years)
BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.
Time frame: During the Evaluation Period (up to 9 years)
The study started to enroll patients in November 2008 and concluded in March 2017.
| Milestone | Brivaracetam |
|---|---|
| Started | 108 |
| Completed | 29 |
| Not completed | 79 |
| Withdrew: Adverse event | 17 |
| Withdrew: Lack of efficacy | 37 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Non-compliance | 4 |
| Withdrew: End of study | 2 |
| Withdrew: Reclassification of seizures | 1 |
| Withdrew: Medical decision to read susar reports | 1 |
| Withdrew: Sponsor decision | 1 |
| Withdrew: Investigator clinical judgement | 1 |
| Withdrew: Patient moved out of study area | 1 |
| Withdrew: Coordinator leaving site | 1 |
| Withdrew: Subject ip non-compliance | 1 |
| Withdrew: Ip stopped by hospital physician | 1 |
Treatment-emergent Adverse events (TEAE) are any untoward medical occurrences in a subject during administered study treatment, whether or not these events are related to study treatment.
| percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years) | 90.7 |
Adverse Events (AE) are any untoward medical occurrences in a subject during administered study treatment, whether or not these events are related to study treatment.
| percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Subjects Who Withdrew Due to Adverse Event (AE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years) | 15.7 |
An SAE was any untoward medical occurrence that, at any dose resulted in death, was life threatening, required in-subject hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.
| percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Subjects With a Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years) | 24.1 |
BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.
| percentage of participants | Brivaracetam (ES) |
|---|---|
| Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 3 Months of the Evaluation Period (up to 9 Years) | 38.89 |
BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.
| percentage of participants | Brivaracetam (ES) |
|---|---|
| Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 6 Months, of the Evaluation Period (up to 9 Years) | 32.41 |
BRV monotherapy is defined as continuous treatment with BRV only (ie, no treatment with another anti-epileptic drug (AED)). Use of rescue AED for a duration of no more than 2 consecutive days will not disqualify a subject from being defined as on continuous monotherapy provided the use of rescue AED does not exceed more than 1 time per week.
| percentage of participants | Brivaracetam (ES) |
|---|---|
| Percentage of Subjects on Continuous Brivaracetam Monotherapy for at Least 12 Months of the Evaluation Period (up to 9 Years) | 25 |
Collected over Adverse events were collected throughout the study (up to 9 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brivaracetam (SS) | 1/108 (0.9%) | 26/108 (24.1%) | 81/108 (75%) |
| Event | Brivaracetam (SS) |
|---|---|
| ConvulsionNervous system disorders | 5/108 |
| Angina pectorisCardiac disorders | 3/108 |
| Atrial fibrillationCardiac disorders | 2/108 |
| CholelithiasisHepatobiliary disorders | 2/108 |
| ContusionInjury, poisoning and procedural complications | 2/108 |
| Grand mal convulsionNervous system disorders | 2/108 |
| Cardiac failure congestiveCardiac disorders | 1/108 |
| Abdominal painGastrointestinal disorders | 1/108 |
| Pancreatitis acuteGastrointestinal disorders | 1/108 |
| VomitingGastrointestinal disorders | 1/108 |
| Event | Brivaracetam (SS) |
|---|---|
| NasopharyngitisInfections and infestations | 19/108 |
| DepressionPsychiatric disorders | 18/108 |
| FatigueGeneral disorders | 17/108 |
| ConvulsionNervous system disorders | 17/108 |
| FallInjury, poisoning and procedural complications | 15/108 |
| HeadacheNervous system disorders | 15/108 |
| AnxietyPsychiatric disorders | 15/108 |
| InsomniaPsychiatric disorders | 15/108 |
| DizzinessNervous system disorders | 14/108 |
| RashSkin and subcutaneous tissue disorders | 13/108 |
Baseline Characteristics refer to the Safety Set which consisted of all subjects who received at least 1 dose of study medication.
| Age, Categorical(Participants) | Brivaracetam |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 103 |
| >=65 years | 5 |
| Age, Continuous(years) | Brivaracetam |
|---|---|
| Mean | 40.8 ± 13 |
| Sex: Female, Male(Participants) | Brivaracetam |
|---|---|
| Female | 56 |
| Male | 52 |
| Race/Ethnicity, Customized(Participants) | Brivaracetam |
|---|---|
| Black or African American | 7 |
| White | 97 |
| Other/Mixed | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Nov 2008, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam